tiprankstipranks
Trending News
More News >

WuXi Biologics Announces Board Composition and Roles

Story Highlights
WuXi Biologics Announces Board Composition and Roles

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Wuxi Biologics (Cayman) ( (HK:2269) ).

WuXi Biologics (Cayman) Inc. has announced the composition of its board of directors and their roles within the company. The board includes executive, non-executive, and independent non-executive directors, with specific members assigned to various committees such as Audit, Remuneration, Nomination, Strategy, and Environmental, Social and Governance. This announcement reflects the company’s commitment to strong governance and strategic oversight, potentially impacting its operational efficiency and stakeholder confidence.

The most recent analyst rating on (HK:2269) stock is a Buy with a HK$30.94 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.

More about Wuxi Biologics (Cayman)

WuXi Biologics (Cayman) Inc. operates in the biopharmaceutical industry, focusing on providing end-to-end solutions for biologics discovery, development, and manufacturing.

Average Trading Volume: 57,849,643

Technical Sentiment Signal: Buy

Current Market Cap: HK$102.5B

For detailed information about 2269 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1